BioCryst Pharmaceuticals BCRX Impairment of long-lived assets
Impairment of long-lived assets at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:TangibleAssetImpairmentCharges.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's impairment of long-lived assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's impairment of long-lived assets?
- BioCryst Pharmaceuticals (BCRX) reported impairment of long-lived assets of $0 in Q4 2025.
- What does impairment of long-lived assets mean?
- Represents the non-cash expense recognized when the carrying amount of a long-lived tangible asset exceeds its recoverable amount. This charge indicates that the asset's future economic benefit has diminished, potentially due to technological obsolescence or changes in business strategy. Frequent impairments may signal poor capital allocation or overly optimistic initial asset valuations.